<html><head><style>div {border : red solid 0.5px}</style><style>span {border : blue dotted 0.5px}</style></head><body><div left="34.02" right="399.08" top="760.96"><span x0="34.02" y0="760.96" x1="399.08" style="x0: 34.02; x1: 39.58; y0: 760.96; y1: 770.96; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">38. Besides enhancing research upstream, integrated with global surveillance, </span><span x0="399.71" y0="760.96" x1="547.16" style="x0: 399.71; x1: 405.08; y0: 760.96; y1: 770.96; width: 5.37; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">a whole range of downstream R&amp;D on medical countermeasures will also have social returns significantly higher than commercial value</span><span x0="541.48" y0="747.96" x1="547.04" style="x0: 541.48; x1: 544.26; y0: 747.96; y1: 757.96; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">, and would be undertaken more swiftly with the aid of the public sector. Examples include: </span></div><div left="55.28" right="66.04" top="708.96"><span x0="55.28" y0="708.96" x1="66.04" style="x0: 55.28; x1: 60.47; y0: 708.96; y1: 718.96; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. </span><span x0="69.45" y0="708.96" x1="148.68" style="x0: 69.45; x1: 75.75; y0: 708.96; y1: 718.96; width: 6.3; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">Efficacy studies </span><span x0="149.44" y0="708.96" x1="547.03" style="x0: 149.44; x1: 152.22; y0: 708.96; y1: 718.96; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">(e.g. studies to ascertain the optimal dosing regimen given vaccine shortages, and to evaluate mix-and-match vaccine doses, should take place in parallel with standard clinical trials, so this information is available as soon as possible.) </span></div><div left="55.28" right="66.8" top="656.96"><span x0="55.28" y0="656.96" x1="66.8" style="x0: 55.28; x1: 61.39; y0: 656.96; y1: 666.96; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">b. </span><span x0="69.45" y0="656.96" x1="215.8" style="x0: 69.45; x1: 75.19; y0: 656.96; y1: 666.96; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">Thermo-stable mRNA vaccines</span></div><div left="55.28" right="65.75" top="630.96"><span x0="55.28" y0="630.96" x1="65.75" style="x0: 55.28; x1: 60.1; y0: 630.96; y1: 640.96; width: 4.82; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">c. </span><span x0="69.45" y0="630.96" x1="212.31" style="x0: 69.45; x1: 75.93; y0: 630.96; y1: 640.96; width: 6.48; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">Repurposing of generic drugs</span></div><div left="69.45" right="328.96" top="604.96"><span x0="69.45" y0="604.96" x1="328.96" style="x0: 69.45; x1: 71.85; y0: 604.96; y1: 614.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">i. A Repurposed Generic Development Program (RGDP)</span><span x0="328.99" y0="609.34" x1="335.67" style="x0: 328.99; x1: 332.24; y0: 609.34; y1: 615.17; width: 3.24; font-size: 5.83; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">30</span><span x0="338.45" y0="604.96" x1="517.94" style="x0: 338.45; x1: 343.27; y0: 604.96; y1: 614.96; width: 4.82; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">could be part of this global ecosystem. </span></div><div left="69.45" right="547.08" top="578.96"><span x0="69.45" y0="578.96" x1="547.08" style="x0: 69.45; x1: 71.85; y0: 578.96; y1: 588.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">ii. Employing public-private partnerships with academic labs, clinical development networks and drug manufacturers, to identify promising drug repurposing targets, coordinate clinical trials, and contract for the manufacturing of promising candidates. </span></div><div left="55.27" right="547.02" top="526.96"><span x0="55.27" y0="526.96" x1="547.02" style="x0: 55.27; x1: 61.38; y0: 526.96; y1: 536.96; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">d. Earlier release of data from clinical trials, before final regulatory approvals, can also shorten the response time for investments in production capacity.</span></div><div left="34.01" right="515.91" top="487.96"><span x0="34.01" y0="487.96" x1="515.91" style="x0: 34.01; x1: 39.57; y0: 487.96; y1: 497.96; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">39. Governments and international organizations should also fund rigorous, quantitative evaluations of the </span><span x0="515.29" y0="487.96" x1="547.13" style="x0: 515.29; x1: 520.11; y0: 487.96; y1: 497.96; width: 4.82; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">causal impact and efficacy of various non-pharmaceutical interventions (NPIs)</span><span x0="388.14" y0="474.96" x1="390.92" style="x0: 388.14; x1: 390.92; y0: 474.96; y1: 484.96; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">.</span></div><div left="55.27" right="546.99" top="448.96"><span x0="55.27" y0="448.96" x1="546.99" style="x0: 55.27; x1: 60.46; y0: 448.96; y1: 458.96; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. These include mask-wearing, ventilation, closure of different institutions (schools, restaurants, public transport), and reduction in contact between people, indoors and outdoors. </span></div><div left="55.27" right="547.01" top="409.96"><span x0="55.27" y0="409.96" x1="547.01" style="x0: 55.27; x1: 61.38; y0: 409.96; y1: 419.96; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">b. This will allow governments to design NPIs appropriately to reduce transmission in a way that is more sustainable over time, and minimize the economic and social costs of achieving targeted transmission reductions.</span></div><div left="34.02" right="489.97" top="351.0"><span x0="34.02" y0="351.0" x1="489.97" style="x0: 34.02; x1: 39.94; y0: 351.0; y1: 371.0; width: 5.92; font-size: 20.0; fill: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Heavy;">(4)  Global governance: to ensure the system is tightly coordinated, properly funded and with clear accountability for outcomes</span></div><div left="34.02" right="547.05" top="269.59"><span x0="34.02" y0="269.59" x1="547.05" style="x0: 34.02; x1: 39.58; y0: 269.59; y1: 279.59; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">40. The current global health architecture is not fit-for-purpose to prevent a major pandemic, nor to respond with speed and force when a pandemic threat emerges. As the Global Preparedness Monitoring Board highlights, the system is fragmented and complex, and lacks accountability and oversight of financing of preparedness. </span></div><div left="34.02" right="547.04" top="217.59"><span x0="34.02" y0="217.59" x1="547.04" style="x0: 34.02; x1: 39.58; y0: 217.59; y1: 227.59; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">41. We must address this by establishing a governance mechanism that integrates all the key players in the global health security ecosystem, with the WHO at the center. </span><span x0="302.57" y0="204.59" x1="547.23" style="x0: 302.57; x1: 305.53; y0: 204.59; y1: 214.59; width: 2.96; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">It should integrate health and finance bodies, within a tightly networked system of responsibility and accountability</span><span x0="353.01" y0="191.59" x1="355.79" style="x0: 353.01; x1: 355.79; y0: 191.59; y1: 201.59; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">.</span></div><div left="55.28" right="547.06" top="165.59"><span x0="55.28" y0="165.59" x1="547.06" style="x0: 55.28; x1: 60.47; y0: 165.59; y1: 175.59; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. Ensuring adequate and sustained investment in normal times, to break the cycle of panic and neglect in pandemic preparedness </span></div></body></html>